APO Research
Talk to an analyst

APO RESEARCH · REPORT

SPECT Radiopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global SPECT Radiopharmaceuticals Market Outlook and Growth Opportunities 2026

20 December 2025197 pages

Choose your research edition.

Industry ResearchSPECT Radiopharmaceuticals Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal SPECT Radiopharmaceuticals Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal SPECT Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal SPECT Radiopharmaceuticals Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal SPECT Radiopharmaceuticals Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global SPECT Radiopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for SPECT Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for SPECT Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for SPECT Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the SPECT Radiopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the SPECT Radiopharmaceuticals market include Siemens Healthineers, NorthStar Medical Radioisotopes, Molecular Imaging, Inc., Lantheus Medical Imaging, IBA Molecular Imaging, GE Healthcare, Eczacibasi-Monrol, Curium Pharma and Cardinal Health, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global SPECT Radiopharmaceuticals market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of SPECT Radiopharmaceuticals and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents SPECT Radiopharmaceuticals revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global SPECT Radiopharmaceuticals market.

SPECT Radiopharmaceuticals Segment by Company

Siemens Healthineers

NorthStar Medical Radioisotopes

Molecular Imaging, Inc.

Lantheus Medical Imaging

IBA Molecular Imaging

GE Healthcare

Eczacibasi-Monrol

Curium Pharma

Cardinal Health

Bracco Imaging

Bayer (Radiology Division)

Advanced Accelerator Applications

SPECT Radiopharmaceuticals Segment by Type

Indium-111 (In-111) Based Agents

Thallium-201 (Tl-201)

Gallium-67 (Ga-67)

Iodine-123 (I-123) Based Agents

Technetium-99m (Tc-99m) Based Agents

SPECT Radiopharmaceuticals Segment by Application

Cardiac Imaging

Brain Imaging

Thyroid Imaging

Infection and Inflammation Imaging

Cancer Imaging

SPECT Radiopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global SPECT Radiopharmaceuticals status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the SPECT Radiopharmaceuticals key companies, revenue, market share, and recent developments.

3. To split the SPECT Radiopharmaceuticals breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions SPECT Radiopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify SPECT Radiopharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze SPECT Radiopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SPECT Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of SPECT Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SPECT Radiopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global SPECT Radiopharmaceuticals industry.

Chapter 3: Detailed analysis of SPECT Radiopharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of SPECT Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of SPECT Radiopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. SPECT Radiopharmaceuticals Industry Trends Table 2. SPECT Radiopharmaceuticals Industry Drivers Table 3. SPECT Radiopharmaceuticals Industry Opportunities and Challenges Table 4. SPECT Radiopharmaceuticals Industry Restraints Table 5. Global SPECT Radiopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global SPECT Radiopharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global SPECT Radiopharmaceuticals Company Ranking, (2024-2026) & (US$ Million) Table 8. Global SPECT Radiopharmaceuticals Key Company Manufacturing Base & Headquarters Table 9. Global SPECT Radiopharmaceuticals Company, Product Type & Application Table 10. Global SPECT Radiopharmaceuticals Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global SPECT Radiopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Indium-111 (In-111) Based Agents Table 15. Significant Companies of Thallium-201 (Tl-201) Table 16. Significant Companies of Gallium-67 (Ga-67) Table 17. Significant Companies of Iodine-123 (I-123) Based Agents Table 18. Significant Companies of Technetium-99m (Tc-99m) Based Agents Table 19. Global SPECT Radiopharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global SPECT Radiopharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global SPECT Radiopharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global SPECT Radiopharmaceuticals Sales Value Share by Type (2021-2026) Table 23. Global SPECT Radiopharmaceuticals Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Cardiac Imaging Table 25. Significant Companies of Brain Imaging Table 26. Significant Companies of Thyroid Imaging Table 27. Significant Companies of Infection and Inflammation Imaging Table 28. Significant Companies of Cancer Imaging Table 29. Global SPECT Radiopharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global SPECT Radiopharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global SPECT Radiopharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global SPECT Radiopharmaceuticals Sales Value Share by Application (2021-2026) Table 33. Global SPECT Radiopharmaceuticals Sales Value Share by Application (2027-2032) Table 34. Global SPECT Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global SPECT Radiopharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global SPECT Radiopharmaceuticals Sales Value Share by Region (2021-2026) Table 37. Global SPECT Radiopharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global SPECT Radiopharmaceuticals Sales Value Share by Region (2027-2032) Table 39. Global SPECT Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global SPECT Radiopharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global SPECT Radiopharmaceuticals Sales Value Market Share by Country (2021-2026) Table 42. Global SPECT Radiopharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global SPECT Radiopharmaceuticals Sales Value Market Share by Country (2027-2032) Table 44. Siemens Healthineers Company Information Table 45. Siemens Healthineers Business Overview Table 46. Siemens Healthineers SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Siemens Healthineers SPECT Radiopharmaceuticals Product Portfolio Table 48. Siemens Healthineers Recent Development Table 49. NorthStar Medical Radioisotopes Company Information Table 50. NorthStar Medical Radioisotopes Business Overview Table 51. NorthStar Medical Radioisotopes SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. NorthStar Medical Radioisotopes SPECT Radiopharmaceuticals Product Portfolio Table 53. NorthStar Medical Radioisotopes Recent Development Table 54. Molecular Imaging, Inc. Company Information Table 55. Molecular Imaging, Inc. Business Overview Table 56. Molecular Imaging, Inc. SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Molecular Imaging, Inc. SPECT Radiopharmaceuticals Product Portfolio Table 58. Molecular Imaging, Inc. Recent Development Table 59. Lantheus Medical Imaging Company Information Table 60. Lantheus Medical Imaging Business Overview Table 61. Lantheus Medical Imaging SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Lantheus Medical Imaging SPECT Radiopharmaceuticals Product Portfolio Table 63. Lantheus Medical Imaging Recent Development Table 64. IBA Molecular Imaging Company Information Table 65. IBA Molecular Imaging Business Overview Table 66. IBA Molecular Imaging SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. IBA Molecular Imaging SPECT Radiopharmaceuticals Product Portfolio Table 68. IBA Molecular Imaging Recent Development Table 69. GE Healthcare Company Information Table 70. GE Healthcare Business Overview Table 71. GE Healthcare SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GE Healthcare SPECT Radiopharmaceuticals Product Portfolio Table 73. GE Healthcare Recent Development Table 74. Eczacibasi-Monrol Company Information Table 75. Eczacibasi-Monrol Business Overview Table 76. Eczacibasi-Monrol SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eczacibasi-Monrol SPECT Radiopharmaceuticals Product Portfolio Table 78. Eczacibasi-Monrol Recent Development Table 79. Curium Pharma Company Information Table 80. Curium Pharma Business Overview Table 81. Curium Pharma SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Curium Pharma SPECT Radiopharmaceuticals Product Portfolio Table 83. Curium Pharma Recent Development Table 84. Cardinal Health Company Information Table 85. Cardinal Health Business Overview Table 86. Cardinal Health SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Cardinal Health SPECT Radiopharmaceuticals Product Portfolio Table 88. Cardinal Health Recent Development Table 89. Bracco Imaging Company Information Table 90. Bracco Imaging Business Overview Table 91. Bracco Imaging SPECT Radiopharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Bracco Imaging SPECT Radiopharmaceuticals Product Portfolio Table 93. Bracco Imaging Recent Development Table 94. Bayer (Radiology Division) Company Information Table 95. Bayer (Radiology Division) Business Overview Table 96. Bayer (Radiology Division) SPECT Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Bayer (Radiology Division) SPECT Radiopharmaceuticals Product Portfolio Table 98. Bayer (Radiology Division) Recent Development Table 99. Advanced Accelerator Applications Company Information Table 100. Advanced Accelerator Applications Business Overview Table 101. Advanced Accelerator Applications SPECT Radiopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Advanced Accelerator Applications SPECT Radiopharmaceuticals Product Portfolio Table 103. Advanced Accelerator Applications Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. SPECT Radiopharmaceuticals Product Image Figure 2. Global SPECT Radiopharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global SPECT Radiopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 4. Global SPECT Radiopharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Indium-111 (In-111) Based Agents Image Figure 8. Thallium-201 (Tl-201) Image Figure 9. Gallium-67 (Ga-67) Image Figure 10. Iodine-123 (I-123) Based Agents Image Figure 11. Technetium-99m (Tc-99m) Based Agents Image Figure 12. Global SPECT Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global SPECT Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global SPECT Radiopharmaceuticals Sales Value Share by Type (2021-2032) Figure 15. Cardiac Imaging Image Figure 16. Brain Imaging Image Figure 17. Thyroid Imaging Image Figure 18. Infection and Inflammation Imaging Image Figure 19. Cancer Imaging Image Figure 20. Global SPECT Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global SPECT Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global SPECT Radiopharmaceuticals Sales Value Share by Application (2021-2032) Figure 23. Global SPECT Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global SPECT Radiopharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America SPECT Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 26. North America SPECT Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe SPECT Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 28. Europe SPECT Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific SPECT Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific SPECT Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America SPECT Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 32. South America SPECT Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa SPECT Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa SPECT Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Indium-111 (In-111) Based Agents
  • Thallium-201 (Tl-201)
  • Gallium-67 (Ga-67)
  • Iodine-123 (I-123) Based Agents
  • Technetium-99m (Tc-99m) Based Agents
Applications
  • Cardiac Imaging
  • Brain Imaging
  • Thyroid Imaging
  • Infection and Inflammation Imaging
  • Cancer Imaging
Companies covered
  • Siemens Healthineers
  • NorthStar Medical Radioisotopes
  • Molecular Imaging, Inc.
  • Lantheus Medical Imaging
  • IBA Molecular Imaging
  • GE Healthcare
  • Eczacibasi-Monrol
  • Curium Pharma
  • Cardinal Health
  • Bracco Imaging
  • Bayer (Radiology Division)
  • Advanced Accelerator Applications

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global SPECT Radiopharmaceuticals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global SPECT Radiopharmaceuticals Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 SPECT Radiopharmaceuticals Market Dynamics
  1. 2.1 SPECT Radiopharmaceuticals Industry Trends
  2. 2.2 SPECT Radiopharmaceuticals Industry Drivers
  3. 2.3 SPECT Radiopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 SPECT Radiopharmaceuticals Industry Restraints
3 SPECT Radiopharmaceuticals Market by Company
  1. 3.1 Global SPECT Radiopharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global SPECT Radiopharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global SPECT Radiopharmaceuticals Company Ranking (2024-2026)
  4. 3.4 Global SPECT Radiopharmaceuticals Company Manufacturing Base and Headquarters
  5. 3.5 Global SPECT Radiopharmaceuticals Company Product Type and Application
  6. 3.6 Global SPECT Radiopharmaceuticals Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global SPECT Radiopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 SPECT Radiopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 SPECT Radiopharmaceuticals Market by Type
  1. 4.1 SPECT Radiopharmaceuticals Type Introduction
  2. 4.1.1 Indium-111 (In-111) Based Agents
  3. 4.1.2 Thallium-201 (Tl-201)
  4. 4.1.3 Gallium-67 (Ga-67)
  5. 4.1.4 Iodine-123 (I-123) Based Agents
  6. 4.1.5 Technetium-99m (Tc-99m) Based Agents
  7. 4.2 Global SPECT Radiopharmaceuticals Sales Value by Type
  8. 4.2.1 Global SPECT Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global SPECT Radiopharmaceuticals Sales Value by Type (2021-2032)
  10. 4.2.3 Global SPECT Radiopharmaceuticals Sales Value Share by Type (2021-2032)
5 SPECT Radiopharmaceuticals Market by Application
  1. 5.1 SPECT Radiopharmaceuticals Application Introduction
  2. 5.1.1 Cardiac Imaging
  3. 5.1.2 Brain Imaging
  4. 5.1.3 Thyroid Imaging
  5. 5.1.4 Infection and Inflammation Imaging
  6. 5.1.5 Cancer Imaging
  7. 5.2 Global SPECT Radiopharmaceuticals Sales Value by Application
  8. 5.2.1 Global SPECT Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global SPECT Radiopharmaceuticals Sales Value by Application (2021-2032)
  10. 5.2.3 Global SPECT Radiopharmaceuticals Sales Value Share by Application (2021-2032)
6 SPECT Radiopharmaceuticals Regional Value Analysis
  1. 6.1 Global SPECT Radiopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global SPECT Radiopharmaceuticals Sales Value by Region (2021-2032)
  3. 6.2.1 Global SPECT Radiopharmaceuticals Sales Value by Region: 2021-2026
  4. 6.2.2 Global SPECT Radiopharmaceuticals Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America SPECT Radiopharmaceuticals Sales Value (2021-2032)
  7. 6.3.2 North America SPECT Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe SPECT Radiopharmaceuticals Sales Value (2021-2032)
  10. 6.4.2 Europe SPECT Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific SPECT Radiopharmaceuticals Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific SPECT Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America SPECT Radiopharmaceuticals Sales Value (2021-2032)
  16. 6.6.2 South America SPECT Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa SPECT Radiopharmaceuticals Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa SPECT Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 SPECT Radiopharmaceuticals Country-level Value Analysis
  1. 7.1 Global SPECT Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global SPECT Radiopharmaceuticals Sales Value by Country (2021-2032)
  3. 7.2.1 Global SPECT Radiopharmaceuticals Sales Value by Country (2021-2026)
  4. 7.2.2 Global SPECT Radiopharmaceuticals Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt SPECT Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt SPECT Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt SPECT Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Siemens Healthineers
  2. 8.1.1 Siemens Healthineers Company Information
  3. 8.1.2 Siemens Healthineers Business Overview
  4. 8.1.3 Siemens Healthineers SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Siemens Healthineers SPECT Radiopharmaceuticals Product Portfolio
  6. 8.1.5 Siemens Healthineers Recent Developments
  7. 8.2 NorthStar Medical Radioisotopes
  8. 8.2.1 NorthStar Medical Radioisotopes Company Information
  9. 8.2.2 NorthStar Medical Radioisotopes Business Overview
  10. 8.2.3 NorthStar Medical Radioisotopes SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  11. 8.2.4 NorthStar Medical Radioisotopes SPECT Radiopharmaceuticals Product Portfolio
  12. 8.2.5 NorthStar Medical Radioisotopes Recent Developments
  13. 8.3 Molecular Imaging, Inc.
  14. 8.3.1 Molecular Imaging, Inc. Company Information
  15. 8.3.2 Molecular Imaging, Inc. Business Overview
  16. 8.3.3 Molecular Imaging, Inc. SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Molecular Imaging, Inc. SPECT Radiopharmaceuticals Product Portfolio
  18. 8.3.5 Molecular Imaging, Inc. Recent Developments
  19. 8.4 Lantheus Medical Imaging
  20. 8.4.1 Lantheus Medical Imaging Company Information
  21. 8.4.2 Lantheus Medical Imaging Business Overview
  22. 8.4.3 Lantheus Medical Imaging SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lantheus Medical Imaging SPECT Radiopharmaceuticals Product Portfolio
  24. 8.4.5 Lantheus Medical Imaging Recent Developments
  25. 8.5 IBA Molecular Imaging
  26. 8.5.1 IBA Molecular Imaging Company Information
  27. 8.5.2 IBA Molecular Imaging Business Overview
  28. 8.5.3 IBA Molecular Imaging SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  29. 8.5.4 IBA Molecular Imaging SPECT Radiopharmaceuticals Product Portfolio
  30. 8.5.5 IBA Molecular Imaging Recent Developments
  31. 8.6 GE Healthcare
  32. 8.6.1 GE Healthcare Company Information
  33. 8.6.2 GE Healthcare Business Overview
  34. 8.6.3 GE Healthcare SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GE Healthcare SPECT Radiopharmaceuticals Product Portfolio
  36. 8.6.5 GE Healthcare Recent Developments
  37. 8.7 Eczacibasi-Monrol
  38. 8.7.1 Eczacibasi-Monrol Company Information
  39. 8.7.2 Eczacibasi-Monrol Business Overview
  40. 8.7.3 Eczacibasi-Monrol SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eczacibasi-Monrol SPECT Radiopharmaceuticals Product Portfolio
  42. 8.7.5 Eczacibasi-Monrol Recent Developments
  43. 8.8 Curium Pharma
  44. 8.8.1 Curium Pharma Company Information
  45. 8.8.2 Curium Pharma Business Overview
  46. 8.8.3 Curium Pharma SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Curium Pharma SPECT Radiopharmaceuticals Product Portfolio
  48. 8.8.5 Curium Pharma Recent Developments
  49. 8.9 Cardinal Health
  50. 8.9.1 Cardinal Health Company Information
  51. 8.9.2 Cardinal Health Business Overview
  52. 8.9.3 Cardinal Health SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cardinal Health SPECT Radiopharmaceuticals Product Portfolio
  54. 8.9.5 Cardinal Health Recent Developments
  55. 8.10 Bracco Imaging
  56. 8.10.1 Bracco Imaging Company Information
  57. 8.10.2 Bracco Imaging Business Overview
  58. 8.10.3 Bracco Imaging SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bracco Imaging SPECT Radiopharmaceuticals Product Portfolio
  60. 8.10.5 Bracco Imaging Recent Developments
  61. 8.11 Bayer (Radiology Division)
  62. 8.11.1 Bayer (Radiology Division) Company Information
  63. 8.11.2 Bayer (Radiology Division) Business Overview
  64. 8.11.3 Bayer (Radiology Division) SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer (Radiology Division) SPECT Radiopharmaceuticals Product Portfolio
  66. 8.11.5 Bayer (Radiology Division) Recent Developments
  67. 8.12 Advanced Accelerator Applications
  68. 8.12.1 Advanced Accelerator Applications Company Information
  69. 8.12.2 Advanced Accelerator Applications Business Overview
  70. 8.12.3 Advanced Accelerator Applications SPECT Radiopharmaceuticals Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Advanced Accelerator Applications SPECT Radiopharmaceuticals Product Portfolio
  72. 8.12.5 Advanced Accelerator Applications Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst